On the stock market since 2021, it operates in the world of health and science. It has 26 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 100% a year over the last 3 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 14 buys and 12 sells. Management buying with its own money is usually read as a good sign.
A loss of $44.3M against $0 in annual sales.
The stock sits at $0.06. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, NKGN sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: NKGN is a high-risk stock — not yet profitable, and its future rides on its product catching on.